The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Open accessPublished version of a preprint
Abstract
Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the identification of novel biomarkers for better personalized medicine. We produced large xenograft cohorts from 85 patient-derived, genetically characterized metastatic colorectal cancer samples (“xenopatients”) to discover novel determinants of therapeutic response and new oncoprotein targets. Serially passaged tumors retained the morphologic and genomic features of their original counterparts. A validation trial confirmed the robustness of this approach: xenopatients responded to the anti-EGFR antibody cetuximab with rates and extents analogous to those observed in the clinic and could be prospectively stratified as responders or nonresponders on the basis of several predictive biomarkers. Genotype–response correlations indicated HER2 amplification specifically in a subset of cetuximab-resistant, KRAS/NRAS/BRAF/PIK3CA wild-type cases. Importantly, HER2 amplification was also enriched in clinically nonresponsive KRAS wild-type patients. A proof-of-concept, multiarm study in HER2-amplified xenopatients revealed that the combined inhibition of HER2 and EGFR induced overt, long-lasting tumor regression. Our results suggest promising therapeutic opportunities in cetuximab-resistant patients with metastatic colorectal cancer, whose medical treatment in the chemorefractory setting remains an unmet clinical need. Significance: Direct transfer xenografts of tumor surgical specimens conserve the interindividual diversity and the genetic heterogeneity typical of the tumors of origin, combining the flexibility of preclinical analysis with the informative value of population-based studies. Our suite of patient-derived xenografts from metastatic colorectal carcinomas reliably mimicked disease response in humans, prospectively recapitulated biomarker-based case stratification, and identified HER2 as a predictor of resistance to anti-epidermal growth factor receptor antibodies and of response to combination therapies against HER2 and epidermal growth factor receptor in this tumor setting. Cancer Discovery; 1(6); 508–23. ©2011 AACR. Read the Commentary on this article by Ciardiello and Normanno, p. 472 This article is highlighted in the In This Issue feature, p. 457
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HER2 overexpression is a negative predictor associated with reduced efficacy of anti-EGFR therapy [31], and >36% of cetuximab-resistant mCRC with wild-type KRAS, NRAS, BRAF, and PI3K was found to display HER2 overexpression [32].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [32]
In the citing paper
“A series of studies have demonstrated that HER2 gene amplification or activating mutations can mediate resistance to anti-EGFR mAbs in CRC [27,178,179].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [27]
In the citing paper
“Preclinical studies have shown that the combination of HER2 and EGFR blockade can lead to CRC tumor regression [27,28,29].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [27]
In the citing paper
“Two independent studies have recently shown that HER2 amplification is a predictor of poor sensitivity to anti-EGFR antibodies [91, 92].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“In retrospective studies, patients with tumors featuring HER2 amplification or heregulin overexpression and treated with cetuximab or panitumumab experienced disease progression and shorter progression-free and overall survival compared with HER2 wild-type cases [91-93].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“only the dual targeting of HER2 and EGFR by combining a small-molecule inhibitor, such as the dual EGFR/HER2 inhibitor lapatinib, with a moAb, such as cetuximab or pertuzumab, induced overt and long-lasting tumor regressions in proof-of-concept trials in HER2-amplified xenopatients [91].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“Increased EGFR gene copy number could predict response among KRAS wild-type patients [53, 91, 111-113]”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“Strong preclinical evidence suggests that dual inhibition of ERBB2 is superior to monotherapy due to enhanced efficacy and reduced therapy resistance4648”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [46]
In the citing paper
“Bertotti et al. identified ERBB2 as a biomarker of resistance to anti-EGFR mAbs [113].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [113]
In the citing paper
“A total of 2–7% of unselected CRCs were found to have ERBB2/mutations, and this number was much higher in KRAS wild-type cases (13.6%) and in KRAS/NRAS/BRAF/PIK3CA quadruple wild-type cases (36% )[13, 113, 114].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [113]
In the citing paper
“Finally, using patient-derived colon cancer xenografts, Bertotti et al. identified HER2 gene amplification as a predictor of resistance to cetuximab among KRAS wild-type tumors (Bertotti et al., 2011).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Bertotti et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationUmar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Rüschoff, J., Fishel, R. A., Lindor, N. M., Burgart, L. J., Hamelin, R., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh034 · Cited by 3,181
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Flagged first, then by citations
1 of the 56 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 944
Filip, S., Vymetalkova, V. P., Petera, J., Vodičková, Ľ., Kubeček, O., John, S., Čečka, F., Krupova, M., Manethová, M., Červená, K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155255 · Cited by 86
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 90
Patient-derived xenografts (PDXs) as model systems for human cancer
Invrea, F., Rovito, R., Torchiaro, E., Petti, C., Isella, C., & Médico, E. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.01.003 · Cited by 79
Self-citationHumanized Mouse Models for the Preclinical Assessment of Cancer Immunotherapy
Wege, A. K. (2018) · BioDrugs · doi:10.1007/s40259-018-0275-4 · Cited by 81
NSCLC and HER2: between lights and shadows
Ricciardi, G. R. R., Russo, A., Franchina, T., Ferraro, G., Zanghì, M., Picone, A., Scimone, A., & Adamo, V. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000379 · Cited by 78
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
Hiroshima, Y., Maawy, A. A., Katz, M. H. G., Fleming, J. B., Bouvet, M., Endo, I., & Hoffman, R. M. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23816 · Cited by 77
Huang, P., Ji, F., Cheung, A. H. K., Fu, K., Zhou, Q., Ding, X. Q., Chen, D., Lin, Y., Wang, L., Jiao, Y., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.07.001 · Cited by 81
Peng, S., Creighton, C. J., Zhang, Y., Sen, B., Mazumdar, T., Myers, J. N., Woolfson, A., Lorenzi, M. V., Bell, D., Williams, M. D., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-198 · Cited by 77
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
Taïeb, J., Jung, A., Bianchi, A. S., Peeters, M., Seligmann, J. F., Zaanan, A., Burdon, P., Montagut, C. O., & Laurent‐Puig, P. (2019) · Drugs · doi:10.1007/s40265-019-01165-2 · Cited by 78
Addressing Patient Specificity in the Engineering of Tumor Models
Bray, L. J., Hutmacher, D. W., & Bock, N. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00217 · Cited by 79
Frequency of HER-2 Positivity in Rectal Cancer and Prognosis
Conradi, L., Styczen, H., Sprenger, T., Wolff, H. A., Rödel, C. M., Nietert, M. M., Homayounfar, K., Gaedcke, J., Kitz, J., Talaulicar, R., et al. (2013) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318272ff4d · Cited by 77
Ried, T., Meijer, G. A., Harrison, D. J., Grech, G., Franch‐Expósito, S., Briffa, R., Carvalho, B. G., & Camps, J. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.07.007 · Cited by 74
Lazzari, L., Corti, G., Picco, G., Isella, C., Montone, M., Arcella, P., Durinikova, E., Zanella, E. R., Novara, L., Barbosa, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3440 · Cited by 74
Self-citationMa, H., Yang, W., Zhang, L., Liu, S., Zhao, M., Zhou, G., Wang, L., Jin, S., Zhang, Z., & Hu, J. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0352-y · Cited by 79
Li, T. X., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00014-6 · Cited by 73
HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer
Xu, J., Meng, Q., Sun, H. X., Zhang, X., Yun, J., Li, B., Wu, S., Li, X., Yang, H., Zhu, H., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04100-0 · Cited by 72
The road to resistance: EGFR mutation and cetuximab
Bardelli, A., & Janne, P. A. (2012) · Nature Medicine · doi:10.1038/nm.2646 · Cited by 71
Self-citationNunes, M., Vrignaud, P., Vacher, S., Richon, S., Lièvre, A., Cacheux, W., Weiswald, L., Massonnet, G., Château‐Joubert, S., Nicolas, A., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1590 · Cited by 74
MicroRNAs in cancer drug resistance: Basic evidence and clinical applications
Ghasabi, M., Mansoori, B., Mohammadi, A., Duijf, P. H. G., Shomali, N., Shirafkan, N., Mokhtarzadeh, A., & Baradaran, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26810 · Cited by 71
Rivera, M., Fichtner, I., Wulf-Goldenberg, A., Sers, C., Merk, J., Patone, G., Merve, K., Kanashova, T., Mertins, P., Hoffmann, J., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.11.005 · Cited by 72
Housini, M., Dariya, B., Ahmed, N., Stevens, A., Fiadjoe, H. K., Nagaraju, G. P., & Basha, R. M. (2023) · Gene · doi:10.1016/j.gene.2023.147857 · Cited by 74
Landi, L. M., & Cappuzzo, F. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.846830 · Cited by 73
Gupta, R., Othman, T., Chen, C., Sandhu, J., Ouyang, C., & Fakih, M. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0441 · Cited by 70
Molecular Testing for Gastrointestinal Cancer
Lee, H. S., Kim, W. H., Kwak, Y., Koh, J., Bae, J. M., Kim, K., Chang, M. S., Han, H. S., Kim, J. M., Kim, H. W., et al. (2017) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2017.01.24 · Cited by 71
Wang, D., Li, J., Zhang, Y., Chen, L., Huang, T., & Cai, Y. (2018) · Genes · doi:10.3390/genes9030155 · Cited by 70
de Vries, G., Rosas-Plaza, X., Meersma, G. J., Leeuwenburgh, V. C., Kok, K., Suurmeijer, A. J. H., van Vugt, M. A. T. M., Gietema, J. A., & de Jong, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-75518-3 · Cited by 72
Takegawa, N., Yonesaka, K., Sakai, K., Ueda, H., Watanabe, S., Nonagase, Y., Okuno, T., Takeda, M., Maenishi, O., Tsurutani, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6498 · Cited by 69
Yu, J., Qin, B., Moyer, A. M., Sinnwell, J. P., Thompson, K. J., Copland, J. A., Marlow, L. A., Miller, J. L., Yin, P., Gao, B., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0920-8 · Cited by 69
Wang, E., Xiang, K., Zhang, Y., & Wang, X.-F. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.10.001 · Cited by 56
Role of targeted agents in metastatic colorectal cancer
Prenen, H., Vecchione, L., & Cutsem, E. V. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0281-x · Cited by 70
Shin, S. H., Lim, D. Y., Reddy, K., Malakhova, M. L., Liu, F., Wang, T., Song, M., Chen, H., Bae, K. B., Ryu, J., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.09.029 · Cited by 70
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
Loree, J. M., Bailey, A. M., Johnson, A. M., Yu, Y., Wu, W., Bristow, C. A., Davis, J. S., Shaw, K. R., Broaddus, R., Banks, K. C., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy067 · Cited by 68
Garrido‐Laguna, I., McGregor, K., Wade, M. L., Weis, J. R., Gilcrease, W., Burr, L., Soldi, R., Jakubowski, L., Davidson, C., Morrell, G., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9947-6 · Cited by 69
Roife, D., Dai, B., Kang, Y., Perez, M. V. R., Pratt, M. F., Li, X., & Fleming, J. B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2936 · Cited by 68
Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review
Brown, K. M., Xue, A., Mittal, A., Samra, J. S., Smith, R. C., & Hugh, T. J. (2016) · Oncotarget · doi:10.18632/oncotarget.11184 · Cited by 69
Suetsugu, A., Katz, M. H. G., Fleming, J. B., Truty, M. J., Thomas, R. M., Moriwaki, H., Bouvet, M., Saji, S., & Hoffman, R. M. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24099 · Cited by 67
Collaborative, P. C. P. (2022) · Cancers · doi:10.3390/cancers14051161 · Cited by 68
Boccaccio, C., & Comoglio, P. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4039 · Cited by 66
Self-citationBrugger, W., & Thomas, M. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.12.014 · Cited by 66
Kocher, B. A., & Piwnica-Worms, D. R. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0503 · Cited by 67
Prognostic and Predictive Molecular Biomarkers in Advanced Colorectal Cancer
Martelli, V., Pastorino, A., & Sobrero, A. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108239 · Cited by 63
In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies
Rosa, R., Monteleone, F., Zambrano, N., & Bianco, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113209990226 · Cited by 67
Szabó, P. M., Vajdi, A., Kumar, N., Tolstorukov, M. Y., Chen, B. J., Edwards, R. H., Ligon, K. L., Chasalow, S. D., Chow, K.-H., Shetty, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-28480-9 · Cited by 71
Molecular therapy of colorectal cancer: Progress and future directions
Weng, W., Feng, J., Qin, H., & Ma, Y. (2014) · International Journal of Cancer · doi:10.1002/ijc.28722 · Cited by 63
Modeling of Patient-Derived Xenografts in Colorectal Cancer
(2017) · doi:10.1158/1535-7163.mct-16-0721 · Cited by 64
Sulaiman, A., & Wang, L. (2017) · Oncotarget · doi:10.18632/oncotarget.22916 · Cited by 63
Bitar, S. A., El-Sabban, M. E., Doughan, S., & Abou-Kheir, W. G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i9.1395 · Cited by 69
The In ovo CAM-assay as a Xenograft Model for Sarcoma
Sys, G. M. L., Lapeire, L., Stevens, N., Favoreel, H. W., Forsyth, R. G., Bracke, M., & Wever, O. D. (2013) · Journal of Visualized Experiments · doi:10.3791/50522 · Cited by 63
From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development
Lieu, C. H., Tan, A. C., Leong, S., Diamond, J. R., & Eckhardt, S. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt209 · Cited by 64
Marangoni, E., Laurent, C., Coussy, F., Botty, R. E., Château‐Joubert, S., Servely, J., de Plater, L., Assayag, F., Dahmani, A., Montaudon, É., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3490 · Cited by 64
The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models
Bladt, F., Friese‐Hamim, M., Ihling, C. H., Wilm, C., & Blaukat, A. (2014) · Cancers · doi:10.3390/cancers6031736 · Cited by 62
Resistance to EGFR-Targeted Therapy: A Family Affair
Vlacich, G., & Coffey, R. J. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.006 · Cited by 61
Suetsugu, A., Katz, M. H. G., Fleming, J. B., Truty, M. J., Thomas, R. M., Saji, S., Moriwaki, H., Bouvet, M., & Hoffman, R. M. (2012) · PubMed · Cited by 61
Durinikova, E., Buzo, K., & Arena, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01981-z · Cited by 61
De Angelis, M. L., Zeuner, A., Policicchio, E., Russo, G., Bruselles, A., Signore, M., Vitale, S., De Luca, G., Pilozzi, E., Boe, A., et al. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0214 · Cited by 60
Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
Nakamura, Y., & Yoshino, T. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0621 · Cited by 61
Blood circulating tumor DNA for non‐invasive genotyping of colon cancer patients
Siravegna, G., & Bardelli, A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.005 · Cited by 60
Self-citationRacial and Ethnic Disparities in Early-Onset Colorectal Cancer Survival
Zaki, T. A., Liang, P. S., May, F. P., & Murphy, C. C. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.05.035 · Cited by 60
Molecular Pathways and Mechanisms of HER2 in Cancer Therapy
Raghav, K. P. S., & Moasser, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0283 · Cited by 65
Establishment of patient-derived cancer xenografts in immunodeficient NOG mice
Chijiwa, T., Kawai, K., NOGUCHI, A., Sato, H., Hayashi, A., Cho, H., Shiozawa, M., Kishida, T., Morinaga, S., Yokose, T., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2997 · Cited by 60
Patient-derived organoids of non-small cells lung cancer and their application for drug screening
Li, Y., Gao, Y., Liang, B., Cao, X., Sun, Z., Yu, J. H., Liu, Z. D., & Han, Y. (2020) · Neoplasma · doi:10.4149/neo_2020_190417n346 · Cited by 61
Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts
Mer, A. S., Ba-Alawi, W., Smirnov, P., Wang, Y. X., Brew, B., Ortmann, J., Tsao, M., Cescon, D. W., Goldenberg, A., & Haibe‐Kains, B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0349 · Cited by 57
The Future of Patient-Derived Tumor Xenografts in Cancer Treatment
Sia, D., Moeini, A., Labgaa, I., & Villanueva, A. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.102 · Cited by 58
Martini, G., Ciardiello, D., Vitiello, P. P., Napolitano, S., Cardone, C., Cuomo, A., Troiani, T., Ciardiello, F., & Martinelli, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102023 · Cited by 59
NOTCH3 Signaling Regulates MUSASHI-1 Expression in Metastatic Colorectal Cancer Cells
Pastò, A., Serafin, V., Pilotto, G., Lago, C., Bellio, C., Trusolino, L., Bertotti, A., Hoey, T. C., Plateroti, M., Esposito, G., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2022 · Cited by 58
Self-citationFujii, S., Magliocco, A. M., Kim, J., Okamoto, W., Kim, J. E., Sawada, K., Nakamura, Y., Kopetz, S., Park, W., Tsuchihara, K., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00154 · Cited by 60
Patient‐derived xenografts as tools in pharmaceutical development
Izumchenko, E., Meir, J., Bedi, A., Wysocki, P., Hoque, M. O., & Sidransky, D. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.354 · Cited by 59
How Can Gastric Cancer Molecular Profiling Guide Future Therapies?
Corso, S., & Giordano, S. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.05.004 · Cited by 58
Wang, X., Ha, D., Yoshitake, R., Chan, Y. S., Sadava, D., & Chen, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168798 · Cited by 64
Precision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 58
Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments
Tang, Y., Li, D., Duan, J.-Y., Sheng, L., & Wang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.926 · Cited by 58
Rubinson, D. A., Höchster, H. S., Ryan, D. P., Wolpin, B. M., McCleary, N. J., Abrams, T. A., Chan, J. A.-W., Iqbal, S., Lenz, H. J., Lim, D. W., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9956-5 · Cited by 56
Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis
Lu, M., Zessin, A. S., Glover, W., & Hsu, D. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169439 · Cited by 56
Adams, R., Brown, E. R., Brown, L. C., Butler, R., Falk, S. J., Fisher, D. J., Kaplan, R. S., Quirke, P., Richman, S. D., Samuel, L. M., et al. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30394-1 · Cited by 56
The design, analysis and application of mouse clinical trials in oncology drug development
Guo, S., Jiang, X., Mao, B., & Li, Q.-X. (2019) · BMC Cancer · doi:10.1186/s12885-019-5907-7 · Cited by 68
Recent advances in personalized colorectal cancer research
Kraus, S. R., Nabiochtchikov, I., Shapira, S., & Arber, N. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.01.025 · Cited by 55
Animal models for exploring the pharmacokinetics of breast cancer therapies
Rashid, O. M., & Takabe, K. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.983073 · Cited by 55
Takegawa, N., & Yonesaka, K. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.03.001 · Cited by 55
Esposito, C., Rachiglio, A. M., La Porta, M. L., Sacco, A., Roma, C., Iannaccone, A., Tatangelo, F., Forgione, L., Pasquale, R., Barbaro, A., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26340 · Cited by 53
Pedersen, M. W., Jacobsen, H. J., Koefoed, K., Dahlman, A., Kjær, I., Poulsen, T. T., Meijer, P., Nielsen, L. S., Horak, I. D., Lantto, J., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0697 · Cited by 54
Alkema, N. G., Tomar, T., Duiker, E. W., Meersma, G. J., Klip, H. G., van der Zee, A. G. J., Wisman, G. B. A., & de Jong, S. (2015) · Scientific Reports · doi:10.1038/srep14495 · Cited by 54
Bianchi, A. S., Loupakis, F., Argilés, G., & Prager, G. W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw191 · Cited by 56
Zhang, L., Liu, F., Weygant, N., Zhang, J., Hu, P., Qin, Z., Yang, J., Cheng, Q., Fan, F., Zeng, Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.013 · Cited by 53
Patient-derived tumor organoids as a platform of precision treatment for malignant brain tumors
Chen, C., Li, H.-W., Wang, Y., Lee, C.-C., Shen, Y.-C., Hsieh, C.-Y., Lin, H., Chen, X.-X., Cho, D., Hsieh, C., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20487-y · Cited by 54
Erriquez, J., Becco, P., Olivero, M., Ponzone, R., Maggiorotto, F., Ferrero, A., Scalzo, M. S., Canuto, E. M., Sapino, A., di Cantogno, L. V., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.06.025 · Cited by 52
Self-citationImproving outcomes in colorectal cancer: Where do we go from here?
Cutsem, E. V., Borràs, J. M., Castells, A., Ciardiello, F., Ducreux, M. P., Haq, A., Schmoll, H., & Tabernero, J. M. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.03.026 · Cited by 57
Troiani, T., Zappavigna, S., Martinelli, E., Addeo, S. R., Stiuso, P., Ciardiello, F., & Caraglia, M. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.756469 · Cited by 53
BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition
de Farias, C. B., Heinen, T. E., dos Santos, R. P., Abujamra, A. L., Schwartsmann, G., & Roesler, R. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.091 · Cited by 57
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors
Gelfo, V., Rodia, M. T., Pucci, M., Dall’Ora, M., Santi, S., Solmi, R., Roth, L. E., Lindzen, M., Bonafè, M., Bertotti, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12354 · Cited by 53
Self-citationYonesaka, K. (2021) · Cancers · doi:10.3390/cancers13051047 · Cited by 55
Mirhadi, S., Tam, S., Li, Q., Moghal, N., Pham, N., Tong, J., Golbourn, B. J., Krieger, J. R., Taylor, P. P., Li, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29444-9 · Cited by 50
Advances in targeted and immunobased therapies for colorectal cancer in the genomic era
Seow, H. F., Yip, W. K., & Fifis, T. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s95101 · Cited by 54
Tirino, G., Pompella, L., Petrillo, A., Laterza, M. M., Pappalardo, A., Caterino, M., Orditura, M., Ciardiello, F., Galizia, G., & Vita, F. D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092659 · Cited by 52
Wu, X., Xu, L., Li, X., Zhou, Y., Han, X., Zhang, W., Wang, W., Guo, W., Liu, W., Xu, Q., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06073-8 · Cited by 53
Zhang, S., Yu, C., Yang, X. Y., Hong, H., Lu, J., Hu, W., Hao, X., Li, S., Aikemu, B., Yang, G., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1476-5 · Cited by 51
Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer
Rizzo, G., Bertotti, A., Leto, S. M., & Vetrano, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01970-2 · Cited by 51
Self-citationMolecular targeted therapy for metastatic colorectal cancer: current and evolving approaches
Li, F., Lin, Y., Li, R., Shen, X., Xiang, M., Xiong, G., Zhang, K., Xia, T., Guo, J., Miao, Z., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1165666 · Cited by 54
Preclinical models for precision oncology
Ibarrola‐Villava, M., Cervantes, A. M. R., & Bardelli, A. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.004 · Cited by 50
Self-citationCurrent and Emerging Biomarkers in Metastatic Colorectal Cancer
Lee, M. K. C., & Loree, J. M. (2019) · Current Oncology · doi:10.3747/co.26.5719 · Cited by 50
Metadata
- Authors
- Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., Ribero, D., Russolillo, N., Muratore, A., Massucco, P., Pisacane, A., Molinaro, L., Valtorta, E., Sartore-Bianchi, A., Risio, M., Capussotti, L., Gambacorta, M., Siena, S., Medico, E., Sapino, A., Marsoni, S., Comoglio, P. M., Bardelli, A., & Trusolino, L.
- Affiliations
- IFOM (IT)
- Authors' Affiliations: 1Laboratory of Molecular Pharmacology, 2Laboratory of Oncogenomics, 3Laboratory of Systems Biology, 4Laboratory of Molecular Genetics, 5Division of Surgical Oncology, 6Unit of Pathology, 7Clinical Coordination Unit, and 8Molecular Clinical Oncology, Institute for Cancer Research and Treatment, Torino; Departments of 9Oncological Sciences and 10Biomedical Sciences and Human Oncology, University of Torino Medical School, Torino; 11Department of Surgery, Mauriziano Umberto I Hospital, Torino; 12FIRC Institute of Molecular Oncology, Milano; 13Division of Pathology, 14Falck Division of Medical Oncology, Ospedale Niguarda Ca' Granda, Milano; and 15Southern Europe New Drug Organization Foundation, Milano, Italy
- ORCID
- Venue
- Cancer Discovery
- Published
- 2011-11-01
- Volume
- 1
- Issue
- 6
- Pages
- 508-523
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W1987443121
- Cited by
- 939
- References
- 56
- Citations by year
- 2026: 24 · 2025: 42 · 2024: 46 · 2023: 79 · 2022: 72 · 2021: 74 · 2020: 71 · 2019: 86 · 2018: 86 · 2017: 90 · 2016: 71 · 2015: 62 · 2014: 60 · 2013: 48 · 2012: 23
- FWCI
- 21.44
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Associazione Italiana per la Ricerca sul Cancro
- Regione Piemonte
- Genentech
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- patient-derived xenografts, metastatic colorectal cancer, cetuximab resistance, HER2 amplification, anti-EGFR therapy, predictive biomarkers, combination therapy, KRAS wild-type, BRAF wild-type, treatment resistance, tumor heterogeneity
- MeSH terms
- Cetuximab, Aged, Aged, 80 and over, Animals, Antibodies, Monoclonal, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Prospective Studies, Biomarkers, Tumor, Colorectal Neoplasms, ras Proteins, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Mice, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
